Navigation Links
Lightlake Therapeutics Commences Two-Week Patient Trial for Treatment of Opioid Overdose with National Institute on Drug Abuse (NIDA)
Date:9/24/2013

LONDON, Sept. 24, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that the Company has begun a two-week clinical trial designed to evaluate the pharmacokinetic properties of Lightlake's intranasal naloxone application in 14 healthy volunteer subjects.

The trial, which began on September 23rd, 2013, is being conducted in partnership with the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health ("NIH").

Naloxone is a medicine currently available through injection that can rapidly reverse the overdose of prescription and illicit opioids. Lightlake is working on a new intranasal delivery system for the delivery of naloxone that could widely expand its availability and use in preventing opioid overdose deaths, a public health problem of epidemic proportion in the U.S. According to the Centers for Disease Control and Prevention, 16,651 people died from prescription opioid overdose in the U.S. in 2010, a significant increase from the 4,030 overdose deaths in 1999.

Assuming favorable outcomes from this study, NIDA plans to file an IND for a larger study. The expected goal of Lightlake's partnership with NIDA is to have an FDA approved intranasal naloxone solution for the reversal of opioid overdoses that can be brought to market within 12 to 18 months.

"We are very pleased to begin our trial with NIDA as we believe this is a key step that will help us to formally deliver an intranasal naloxone spray aimed at reversing opioid overdoses to the healthcare community," stated Dr. Roger Crystal, CEO of Lightlake. "Naloxone is the ideal opioid antagonist and we are confident that the data from this trial can also be used to supply critical data for other Lightlake studies that involve va
'/>"/>

SOURCE Lightlake Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
2. Moderna Therapeutics Named a "Fierce 15" Biotech Company for 2013
3. Protagonist Therapeutics Expands Series B Financing to $18 Million with Addition of $4 Million from Pharmstandard
4. PTC Therapeutics to Present at European Pediatric Neurology Society Congress
5. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
6. Adheron Therapeutics Names New Senior Leadership
7. Case Report Suggests Microbiome Therapeutics NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control
8. Echo Therapeutics Sends Response to Shareholder Letter
9. Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
10. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
11. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Biomatrica, the leader in room,temperature biological sample stabilization, announced ... President of Sales and Marketing.,Biomatrica,s interim Vice President of ... of the company and will continue to serve as,an ... brings fourteen years of sales and marketing experience in,the ...
... operations during the first ... ... in US dollars, QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - Atrium Innovations ... for health and nutrition industries, announced today,his financial results for the first ...
... 5 NeoGenomics, Inc. (OTC,Bulletin Board: NGNM) announced today that ... Wednesday, May 7, 2008., The Company has scheduled ... on May 7, 2008, at 11:00 AM EDT. Interested ... least,five minutes prior to the call. A replay of ...
Cached Biology Technology:Trisha Dowling Joins Biomatrica as Vice President, Sales and Marketing 2Atrium shows a strong financial performance for its first quarter 2Atrium shows a strong financial performance for its first quarter 3Atrium shows a strong financial performance for its first quarter 4Atrium shows a strong financial performance for its first quarter 5NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008 2
(Date:4/24/2014)... brain infection caused by fungus could now be treated in ... University of Liverpool scientists. , Cryptococcus a ... relatively neglected in medical research. They are found in ... East Asia and mainly affect people with weakened immune systems. ... The University research team has tested the effects of the ...
(Date:4/24/2014)... largest river turtle in North America, weighing in at ... Now researchers from Florida and the University of Vermont ... but three. , Examining museum specimens and wild turtles, ... reptile. , Once heavily hunted for turtle meat ... Soup in the 1960s the riverine populations have ...
(Date:4/23/2014)... allergies and other chronic inflammatory disorders among people of ... their reduced exposure to the microbes that thrive in ... The article, published in the journal Clinical & ... centers who have less access to green spaces may ... caused by immune system dysfunction. , When our immune ...
Breaking Biology News(10 mins):Treatment for deadly yeast disease reduced to 3 days 2Two new US turtle species described 2Two new US turtle species described 3Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3
... Brookhaven National Laboratory, the New York Structural Biology ... atomic crystal structure and functional mechanism of an ... as drugs, industrial chemicals, and toxic compounds from ... help scientists understand how these compounds are eliminated ...
... improve on milk, but animal scientists at the University ... transgenic goats, which carry the gene for an antibacterial ... bacteria in young goats and pigs that were fed ... one day lead to milk that protects infants and ...
... are preparing to stockpile vaccines against H5N1, the strain ... next flu pandemic. But will these vaccines remain effective ... the July 15 issue of The Journal of Infectious ... PhD, Robert G. Webster, PhD, and coworkers at St. ...
Cached Biology News:Scientists take 'snapshots' of enzyme action 2Transgenic goat's milk offers hope for tackling children's intestinal disease 2Transgenic goat's milk offers hope for tackling children's intestinal disease 3Experimental vaccine protects lab animals against several strains of H5N1 2
... through the extracellular matrix (ECM) is an ... cells initiate invasion by adhering to and ... Proteolytic enzymes, such as MMP collagenases, dissolve ... membrane) surrounding the blood vessels to allow ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
Kit containing MACS equipment and reagents for immunopurification of proteins....
... of poor quality running into billions ... are under increasing pressure to reduce ... the microscopic distribution of ingredients is ... such as dissolution, stability, bio-availability and ...
Biology Products: